Mitochondrial permeability transition pore: a snapshot of a therapeutic target
Mario Zoratti,Lucia Biasutto,Sofia Parrasia,Ildikó Szabo
DOI: https://doi.org/10.1080/14728222.2024.2306337
IF: 6.797
2024-01-20
Expert Opinion on Therapeutic Targets
Abstract:KEYWORDS: The mitochondrial permeability transition (MPT) is defined as the loss of inner membrane a specific impermeability and transmembrane potential, due to the sustained opening of a large pore (the MPTP). The pore (also nicknamed Mitochondrial MegaChannel, MMC) has been characterized decades ago in studies with isolated mitochondria and – by our group – by single-channel patch-clamp on rat liver mitoplasts. Very similar activity (the Multi-Conductance Channel, MCC) was independently described by K.W. Kinnally's group (revs [ Citation 1 , Citation 2 ]). The awakening of this megachannel is elicited by increases in matrix Ca 2+ levels and is potentiated by other agents/processes, the major one being oxidative stress. The equivalent diameter of the pore can be as large as 3 nm but the channel exhibits a variety of sizes. In samples of isolated mitochondria, the molecular weight of permeating molecules increases as a function of the inducing Ca 2+ concentration and of the time elapsed since induction. Partial removal of the OMM would instead tend to decrease it [ Citation 3 ]. Prolonged opening is accompanied by depolarization, release of matrix components, further generation of reactive oxygen species (ROS), morphological changes (swelling, fragmentation of the mitochondrial network), decrease in cellular ATP levels, activation of mitophagy and, eventually, cell death. MPTP opening has been proposed to be involved in ischemia/reperfusion injury (IRI), aging and aging-associated neurodegenerative diseases, chronic stress syndrome, traumatic brain injury, muscular dystrophy, diabetes, cirrhosis, pancreatitis, osteoporosis, and more. In addition, cancer cells deploy desensitization mechanisms which help cancer growth and dispersion, and which may oppose chemotherapy. Inhibiting or activating the MPTP is therefore an exceptionally relevant pharmacological goal. As such, it has received much attention, but so far successes in pre-clinical models have not been accompanied by a proportionate impact in clinical practice. The effort continues. The MPTP is also believed to have physiological and protective roles under normal circumstances, by opening transiently to act as a 'Ca 2+ release valve,' preventing mitochondrial Ca 2+ overload, and tuning mitochondrial function [ Citation 4 , Citation 5 ]. This function appears to be particularly important in cardiac myocytes.
pharmacology & pharmacy